Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Jeppe Ragnar, Andersen"'
Autor:
Anne-Christine Bay-Jensen, Asger Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Bente Juhl Riis, Claus Christiansen, Martin Michaelis, Hans Guehring, Christoph Ladel, Morten A. Karsdal
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract The heterogeneous nature of osteoarthritis (OA) and the need to subtype patients is widely accepted in the field. The biomarker CRPM, a metabolite of C-reactive protein (CRP), is released to the circulation during inflammation. Blood CRPM le
Externí odkaz:
https://doaj.org/article/f2558c7d1f10478b8c5f1554b53e37d1
Autor:
Asger Reinstrup Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Simone Faurholt Simonsen, Kamilla Mundbjerg, Betina Helmer, Bente Juel Riis, Morten Asser Karsdal, Claus Christiansen
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Menopause is associated with detrimental changes in turnover of bone and cartilage and a variety of symptoms with negative impact on the quality of life. Naturally occurring isoflavones from Radix Pueraria lobata, Kudzu root, may possess
Externí odkaz:
https://doaj.org/article/fe2b4aa4d4d844318a655c0fe7a44ea6
Autor:
Asger Reinstrup Bihlet, Inger Byrjalsen, Anne-Christine Bay-Jensen, Jeppe Ragnar Andersen, Claus Christiansen, Bente Juel Riis, Morten A. Karsdal
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Abstract Background Excessive cartilage degradation is a known characteristic of osteoarthritis (OA). Biochemical markers, such as uCTX-II, have been shown to be associated with disease severity, yet the tissue origin of CTX-II has been disputed. Thi
Externí odkaz:
https://doaj.org/article/b0b4a66efd5a435386b7e6a1053b1c89
Autor:
Asger Reinstrup Bihlet, Inger Byrjalsen, Anne-Christine Bay-Jensen, Jeppe Ragnar Andersen, Claus Christiansen, Bente Juel Riis, Ivo Valter, Morten A. Karsdal, Marc C. Hochberg
Publikováno v:
BMC Musculoskeletal Disorders, Vol 19, Iss 1, Pp 1-11 (2018)
Abstract Background Pain is the principal clinical symptom of osteoarthritis (OA), and development of safe and effective analgesics for OA pain is needed. Drug development of new analgesics for OA pain is impaired by substantial change in pain in pat
Externí odkaz:
https://doaj.org/article/aaa04b30ab1b4610b042db1c2904669f
Autor:
Jeppe Ragnar Andersen, Christoffer von Sehested, Inger Byrjalsen, Sara Popik, Anne Bo Follin, Asger Reinstrup Bihlet
Publikováno v:
British journal of clinical pharmacology.
Source Data Verification (SDV) has been reported to account for up to 25% of the budget in Clinical Trials (CT) and cost-benefit of SDV has been questioned. Guidelines for Risk-Based Monitoring (RBM) were published in 2013 by agencies and in 2016, IC
Autor:
Henning B. Nielsen, Christian S. Thudium, Abigail L. Mackey, Inger Byrjalsen, J.J. Bjerre-Bastos, Asger Reinstrup Bihlet, Morten A. Karsdal, Mikael Boesen, Jeppe Ragnar Andersen
Publikováno v:
European Journal of Applied Physiology. 121:2799-2809
To investigate acute changes in biochemical markers of bone and cartilage turnover in response to moderate intensity exercise with and without joint impact in healthy human subjects. A randomized, cross-over, exploratory, clinical study was conducted
Autor:
Henning Bliddal, Mikael Boesen, Jeppe Ragnar Andersen, Asger Reinstrup Bihlet, J.J. Bjerre-Bastos, Morten Karsdal, Anne-Christine Bay-Jensen
Publikováno v:
Translational Sports Medicine. 3:384-394
Autor:
Asger Reinstrup, Bihlet, Inger, Byrjalsen, Jeppe Ragnar, Andersen, Fredrik, Öberg, Christina, Herder, Mike A, Bowes, Philip G, Conaghan
Publikováno v:
Clinical and experimental rheumatology. 40(5)
Osteoarthritis (OA) development programmes face challenges due to discordance between structural changes and symptoms. A novel cathepsin-K inhibitor, MIV-711, recently reported structural benefits, but did not demonstrate a significant difference fro
Autor:
Felix Eckstein, M. Michaelis, Hans Guehring, Philip G Conaghan, Marc C. Hochberg, Christoph Ladel, Asger Reinstrup Bihlet, Benjamin Daelken, Oliver Guenther, Jeppe Ragnar Andersen, Inger Byrjalsen, Victor Ona, F. Moreau
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveThe FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a06dd4594885053d53674425ae5b461
https://eprints.whiterose.ac.uk/174463/3/annrheumdis-2020-219181.full.pdf
https://eprints.whiterose.ac.uk/174463/3/annrheumdis-2020-219181.full.pdf
Autor:
Jeppe Ragnar Andersen, M. Michaelis, Asger Reinstrup Bihlet, Claus Christiansen, Inger Byrjalsen, Bente Juhl Riis, Christoph Ladel, Anne-Christine Bay-Jensen, Morten A. Karsdal, Hans Guehring
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
The heterogeneous nature of osteoarthritis (OA) and the need to subtype patients is widely accepted in the field. The biomarker CRPM, a metabolite of C-reactive protein (CRP), is released to the circulation during inflammation. Blood CRPM levels have